Effects of RT234 on Exercise Parameters Accessed by CPET in Subjects With PAH
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Pulmonary Arterial Hypertension
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
Consequences of pulmonary arterial hypertension are significant limitations in cardiorespiratory fitness (CRF), exercise capacity, as well as profound dyspnea with physical exertion. The objective of the present study is to assess the ability of a single inhaled dose of RT234 to acutely improve prim...
Consequences of pulmonary arterial hypertension are significant limitations in cardiorespiratory fitness (CRF), exercise capacity, as well as profound dyspnea with physical exertion. The objective of the present study is to assess the ability of a single inhaled dose of RT234 to acutely improve primary CPET measures of CRF and exercise capacity, and to lower the sensation of dyspnea with physical exertion compared to baseline CPET measures.
Tracking Information
- NCT #
- NCT04266197
- Collaborators
- Argint International
- Precision For Medicine
- Investigators
- Study Director: Edwin Parsley, D.O. Respira Therapeutics, Inc.